Kalaris Therapeutics, Inc. - Common Stock, par value $0.0001 per share (KLRS)

Q: What does CUSIP 482929106 represent in this 13F holders report?

CUSIP 482929106 is the security identifier for KLRS - Kalaris Therapeutics, Inc. - Common Stock, par value $0.0001 per share used to aggregate holder disclosures.

Q: How many institutions held KLRS - Kalaris Therapeutics, Inc. - Common Stock, par value $0.0001 per share in Q1 2025?

31 institutional investors reported KLRS - Kalaris Therapeutics, Inc. - Common Stock, par value $0.0001 per share for Q1 2025. Use the holders table for investor-level position and value details.

CUSIP: 482929106

Q1 2025 13F Holders as of 31 Mar 2025

Security type / class: Equity / Common Stock, par value $0.0001 per share
Total 13F shares: 13,874,350
Total 13F value: $111,411,096
Share change: +13,874,223
SEC-reported price per share: $8.03
Number of holders: 31
Value change: +$111,410,076
Number of buys: 30
Shares outstanding: 23,815,800

Security key

482929106

Report period

Q1 2025

Institutions

Top holders

KLRS full security history Ownership snapshot Full 13F holder table Newer quarter: Q3 2025 Kalaris Therapeutics, Inc. SEC filings Kalaris Therapeutics, Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Reporting periods

Holder history for CUSIP 482929106

Newer quarter: Q3 2025

Recent filing periods:

Q3 2026 Q2 2026 Q1 2026 Q4 2025 Q3 2025

Ownership snapshot

Top reported holders of KLRS - Kalaris Therapeutics, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

GILEAD SCIENCES, INC.

Disclosed value leader

Ansbert Gadicke

Comparable rows

2/15

Latest evidence

21 Feb 2025

3/4/5 13D/G 13F Lead comparable stake: 3.9% 13 rows are not safely comparable across share classes. 13D/G row: GILEAD SCIENCES, INC. Showing 1-6 of 15 holder rows.

Quick read

GILEAD SCIENCES, INC. leads the comparable SEC ownership view at 3.9%.

2 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens GILEAD SCIENCES, INC.'s linked filing trail.

Comparable ownership Top 2

GILEAD SCIENCES, INC. 3.9%

EcoR1 Capital, LLC 1.1%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
GILEAD SCIENCES, INC.	3/4/5 13D/G 13F 10%+ Owner · Company 3/4/5 13D/G 13F	3.9% Reported 13D/G · 18 Mar 2025	$11,158,950 16,635,286 shares	—	27 Jun 2023
EcoR1 Capital, LLC	13F 13D/G Company 13F 13D/G	1.1% Reported 13D/G · 31 Mar 2025	$3,947,926 408,688 shares	—	31 Dec 2024
Ansbert Gadicke	3/4/5 Director, 10%+ Owner 3/4/5	— denominator unverified	$11,205,689 16,704,963 shares	—	28 Jul 2022
ElevateBio, LLC	3/4/5 Director, 10%+ Owner 3/4/5	— denominator unverified	$11,185,433 16,674,766 shares	—	28 Jul 2022
Vikas Sinha	3/4/5 Officer Title: President, Chief Financial Officer and Chief Executive Officer, Director, 10%+ Owner 3/4/5	— denominator unverified	$7,799,858 774,118 shares	—	21 Feb 2025
F2 MG Ltd	3/4/5 Director, 10%+ Owner 3/4/5	— denominator unverified	$6,592,683 9,828,091 shares	—	28 Jul 2022

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2025

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions

13,874,350

Rows available

Investor	Option	Weight %	Change %	SEC-reported value	* Price	Shares	Share Change	Activity	Report Period

^* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q1 2025 vs Q2 2026 Across Filers

Q2 2026 holders

Q1 2025 holders

Holder diff

-24

Investor	Q2 2026 Shares	Q1 2025 Shares	Share Diff	Share Chg %	Q2 2026 value	Q1 2025 value	Value change	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend